Evidence map›Paper›PMID 40493881›Full record

ArticleBlood2025

The T follicular helper/T follicular helper regulatory pathway in FVIII immune responses in mice.

Weiqing Jing, Jocelyn A Schroeder, Saurabh Kumar, Juan Chen, Yuanhua Cai, Lynn M Malec, Alexander L Dent, Weiguo Cui, Qizhen Shi

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weiqing JingThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0002-3008-9873
Jocelyn A SchroederThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0001-8953-5201
Saurabh KumarThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0002-2143-6415
Juan ChenThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.
Yuanhua CaiThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.
Lynn M MalecThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0001-9173-7179
Alexander L DentDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0001-7226-8936
Weiguo CuiThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0003-1562-9218
Qizhen ShiThrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0003-1548-0708

Funding

Platelet-Derived FVIII Gene Therapy of Hemophilia AR01HL102035 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Qizhen Shi · 2010 to 2026
$7.0M
NHLBI NIH HHS R01 HL102035
6 · The paper itself

Abstract

abstarctDeveloping anti-factor VIII (FVIII) inhibitory antibodies (inhibitors) are a significant complication of FVIII protein replacement therapy in hemophilia A. Our previous study demonstrated that follicular helper T (TFH) cells play a critical role in FVIII inhibitor development. Follicular regulatory T (TFR) cells are a subset of forkhead box protein P3 positive (Foxp3+) T cells identified in the germinal center that can modulate TFH cell activation of B cells and antibody development. Here, we report that FVIII immunization significantly increases the TFR cells in the spleens of FVIII inhibitor-producing FVIIInull mice compared with saline-treated controls and non-inhibitor-producing animals. The TFH/TFR ratio significantly increased in FVIII inhibitor-producing mice. The emergence of TFR cells correlated with titers of FVIII inhibitors in FVIII-immunized mice. Using TFR-deficient Foxp3Cre+Bcl6fl/fl (Bcl6FC) mice, we found that the loss of TFR cells led to significantly decreased FVIII inhibitors compared with wild-type (WT) mice on FVIII immunization (24 ± 16 and 131 ± 114 Bethesda unit (BU)/mL, respectively) but not total anti-FVIII IgG levels and that TFR cells regulated IgG subclass switching and FVIII-specific B-cell responses. Interestingly, on FVIII immunization, mice with phosphatase and tensin (Pten) deficiency in Foxp3+ cells (Foxp3Cre+Ptenfl/fl), a model with augmented TFR cells, developed markedly lower FVIII inhibitor titers (8.1 ± 8.6 BU/mL) than WT controls. When CD4Cre+Bcl6fl/fl mice, a TFH- and TFR-deficient model, were immunized with FVIII, none of the animals developed FVIII inhibitors. In conclusion, FVIII immunization induces TFR cell activation and expansion. TFR cells have a dual function in regulating the development of FVIII inhibitors, and the TFH/TFR pathway is pivotal in FVIII inhibitor development in mice.

Indexed as

Factor VIIIT Follicular Helper CellsT-Lymphocytes, Helper-InducerT-Lymphocytes, RegulatoryAnimalsB-LymphocytesForkhead Transcription FactorsGerminal CenterHemophilia AMiceMice, Inbred C57BLFactor VIIIForkhead Transcription Factors

Identifiers

PMID40493881
PMCPMC12412428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.